| Objective: Acute myeloid leukemia(acute myeloid leukemia,AML)is a malignant haematological disorder with abnormal clonal proliferation of the haematopoietic stem cell system,of which the treatment of AML in the elderly remains a great challenge at present.The aim of this study is to investigate the efficacy and safety of chemotherapy combined with microtransplantation in the treatment of AML in the elderly,and to provide a careful analysis of chemotherapy combined with microtransplantation in the treatment of AML in the elderly in the light of the relevant literature,so as to provide some assistance in the choice of treatment for AML in the elderly.Methods: This study retrospectively collected the clinical data of elderly AML patients who received chemotherapy combined with microtransplantation at the First Affiliated Hospital of Wannan Medical College and the Second Affiliated Hospital of Wannan Medical College between December 1,2019 and December 31,2022,including the general characteristics of the patients,the Franco-British-American staging of AML,the results of relevant adjuvant tests and follow-up data to observe the patients’ remission,survival,adverse effects,and the occurrence of acute and chronic graft-versus-host disease after receiving chemotherapy combined with microtransplantation.The clinical data include the general characteristics of the patients,the FAB staging of AML,the relevant adjuvant finding and the follow-up data to observe the remission,survival,adverse effects and the occurrence of acute and chronic graft-versus-host disease of patients treated with chemotherapy combined with microtransplantation.Results: A total of 10 elderly AML patients were retrospectively collected in this study,9 of whom were primary patients and 1 was in remission,and a total of 17 microtransplantation sessions were performed.During the induction remission treatment session,7 of the 9 patients(77.8%)achieved complete remission and 2patients did not achieve remission and later developed death due to disease progression.The mean recovery time for neutrophils during the induction remission treatment phase was 13.00 d,with a median time of 13.50 d(7d to 20d);the mean recovery time for platelets was 14.25 d,with a median recovery time of 13.00 d(5d to 24d).No acute or chronic graft-versus-host disease was observed during any of the micrograft treatments,and no treatment-related deaths occurred,with a high number of recurrent cases occurring during the follow-up phase.Conclusion: Through the observation of the effectiveness of micrograft treatment in our hospital combined with previous related literature,we found that micrograft treatment in the treatment of AML in the elderly can improve the remission rate,accelerate the recovery of haematopoietic function and reduce death due to opportunistic infection and bleeding,which is a safe and effective treatment modality.Graft-versus-host disease rarely occurs during microtransplantation,even without graft-versus-host disease prophylaxis,but the disease cannot be ignored in clinical work.The combination of targeted drugs,novel combination agents and micrografting could provide more new options for the treatment of AML in the elderly. |
PDF Full Text Request